Name: Latest research reports of Eris Lifesciences Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Eris Lifesciences Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Eris Lifesciences Ltd.

NSE: ERIS | BSE: 540596 | ISIN: INE406M01024 | Industry: Pharmaceuticals
| Turnaround Potential

1808.1000 5.00 (0.28%)

NSE Aug 05, 2025 15:31 PM

72.03% Gain from 52W Low

Volume: 308.0K

High volume today

Eris Lifesciences Ltd.

07 Aug 2023

1808.10

0.28%

Eris Lifesciences (BUY): In-line quarter; margins moving back on track

Buy: Eris Lifesciences Ltd.

Target

BOB Capital Markets Ltd.

Q1 revenue/PAT in line but operating margin ahead of consensus at 36.4% (+395bps YoY)

Eris Lifesciences Ltd. has gained 61.29% in the last 1 Year